Fig. 5: An engineered human IL-33 therapeutic stimulates TLSs and anti-tumour activity in PDAC.
From: IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer
a, ST2 activation in HEK blue human IL-33 reporter cells with H-rIL-33, H-e-rIL-33 and H-e-rIL-33–Fc. EC50, half-maximal effective concentration. b–d, The intratumoural KLRG1+ ILC2 frequency (b), TLS density (c) and tumour volume (d) in PDAC mice treated with vehicle, mouse rIL-33, H-rIL-33 or escalating H-e-rIL-33–Fc. Curves in a were fit by nonlinear regression. Data were collected at 3–4 weeks (b and c) after tumour implantation, pooled from ≥2 independent experiments with n ≥ 3 mice per group with consistent results. n values represent the number of individual tumours from individual mice. The horizontal bars show the median. P values were calculated using extra-sum-of-squares F test (a) and two-way ANOVA with Tukey’s multiple-comparison correction test (b–d).
